文献速递淋巴瘤

喷司他丁联合环磷酰胺和利妥昔单抗治疗惰性非霍奇金淋巴瘤的长期总生存和无进展生存

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.
PubMed 文献 · Br J Haematol · 2019-02-28

这项前瞻性II期试验对83例既往未治疗的晚期惰性非霍奇金淋巴瘤患者采用喷司他丁、环磷酰胺和利妥昔单抗(PCR)方案,中位随访超过108个月。108个月无进展生存率在滤泡性淋巴瘤、边缘区淋巴瘤和小淋巴细胞淋巴瘤分别为71%、67%和15%;10年总生存率为64%,滤泡性淋巴瘤94%、边缘区淋巴瘤66%、小淋巴细胞淋巴瘤39%。

要点

  • PCR方案在惰性非霍奇金淋巴瘤中10年随访显示有效且可耐受。
  • 滤泡性淋巴瘤10年无进展生存率71%、总生存率94%。
  • 小淋巴细胞淋巴瘤10年无进展生存率15%、总生存率39%。

核心结论

  • 10年随访分析证实PCR是惰性非霍奇金淋巴瘤有效、稳健且可耐受的治疗方案。

研究设计与样本

  • 前瞻性II期试验,纳入83例既往未治疗的晚期惰性非霍奇金淋巴瘤患者,中位随访超过108个月,采用意向性治疗分析。

主要发现

  • 108个月无进展生存率:滤泡性淋巴瘤71%,边缘区淋巴瘤67%,小淋巴细胞淋巴瘤15%。
  • 治疗前β2微球蛋白<2·2 mg/l者10年无进展生存率71%,≥2·2 mg/l者21%。
  • 无骨髓受累者10年无进展生存率72%,有骨髓受累者29%。
  • 10年总生存率64%,滤泡性淋巴瘤94%、边缘区淋巴瘤66%、小淋巴细胞淋巴瘤39%,差异显著。
  • 长期毒性包括18例(21·7%)患者发生第二恶性肿瘤,2例(2·4%)在接受额外化疗后发生骨髓增生异常综合征。

临床怎么用

  • 原文结论认为PCR是惰性非霍奇金淋巴瘤有效、稳健且可耐受的治疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In a prospective phase II trial, pentostatin combined with cyclophosphamide and rituximab (PCR) induced strong responses and was well-tolerated in previously untreated patients with advanced-stage, indolent non-Hodgkin lymphoma (iNHL). After a median patient follow-up of more than 108 months, we performed an intent-to-treat analysis of our 83 participants. Progression-free survival (PFS) rates at 108 months for follicular lymphoma (FL), marginal zone lymphoma (MZL) and small lymphocytic lymphoma (SLL) were 71%, 67% and 15%, respectively, and were affected by clinicopathological characteristics. Ten-year PFS rates for those with beta-2-microglobulin levels <2·2 and ≥2·2 mg/l prior to treatment were 71% and 21%, respectively. Patients without bone marrow involvement had 10-year PFS rates of 72% vs. 29% for those with involvement. At time of analysis, the median overall survival (OS) had not been reached. The OS rate was 64% at 10 years and differed significantly based on histology: 94% for FL, 66% for MZL and 39% for SLL. Long-term toxicities included 18 (21·7%) patients with second malignancies and 2 (2·4%) who developed myelodysplastic syndrome after receiving additional lines of chemotherapy. Our 10-year follow-up analysis confirms that PCR is an effective, robust and tolerable treatment regimen for patients with iNHL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Khashab T, Hagemeister F, Romaguera JE, et al. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol. 2019. PMID: 30820940. doi:10.1111/bjh.15814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。